TAM Targeting Peptides on Solid Particles for TNBC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for triple-negative breast cancer (TNBC) are inadequate due to the aggressive nature and high heterogeneity of the disease, with tumor-associated macrophages (TAMs) playing a significant role in tumor progression and poor disease outcomes, necessitating a novel therapeutic approach that targets TAMs.
Innovation Solution
Development of tumor-associated macrophage (TAM) targeting peptides, such as CSSTRESAC, CRYSAARSC, CRGFVVGRC, and CQRALMIAC, attached to or displayed on solid particles like bacteriophages or nanoparticles, which are administered to selectively target and treat tumors infiltrated with TAMs, potentially using therapeutic or suicide genes like TNF or HSVtk to alter the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy and immunotherapy are used to treat TNBC, then some tumor cells may be killed, but the treatment fails to effectively address TAM-mediated tumor progression and results in poor disease outcomes
Solution Approach 1:
The patent uses a targeting peptide as an intermediary molecule that specifically binds to TAMs. This peptide serves as a mediator between the therapeutic agent and the target cells, enabling selective delivery of therapy to TAMs while sparing other cells. The peptide acts as a bridge that overcomes the non-specificity of conventional therapies.
Solution Approach 2:
The patent applies local quality by concentrating the therapeutic effect specifically at the TAM location. The composition delivers therapy locally to TAM-infiltrated tumor regions rather than systemically affecting all cells. This localized approach addresses the specific problem of TAM-mediated progression without unnecessarily affecting other tissue.
2Object-affected harmful factors
If the tumor microenvironment is highly infiltrated with TAMs, then tumor progression is promoted and disease outcome deteriorates, but conventional treatments cannot effectively penetrate or target this protective microenvironment
Solution Approach 1:
The targeting peptide on the solid particle surface enables the composition to self-target TAMs autonomously. The peptide inherently recognizes and binds to TAM-specific markers without requiring external guidance or complex delivery systems. This self-targeting capability overcomes the barrier of delivering therapy to the protective tumor microenvironment.
3Reliability
If solid particles with TAM-targeting peptides are administered, then TAMs can be selectively targeted and therapeutic effect is enhanced, but the complexity of the treatment composition increases
Solution Approach 1:
The patent segments the therapeutic system into distinct functional components: a solid particle carrier and a TAM-targeting peptide. This segmentation allows each component to be optimized independently - the particle provides therapeutic payload and the peptide provides targeting specificity. The modular design simplifies the overall complexity compared to attempting to create a single complex targeted molecule.
Data Source
AI summary
In one aspect, the present disclosure relates to tumor associated macrophage (TAM) targeting peptide. In another aspect, the present disclosure relates to a method of targeting a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle. In yet another aspect, the present disclosure relates to a method of treating a tumor infiltrated with a TAM in a subject, the method comprising administering to the subject a TAM targeting peptide attached to and/or displayed on the surface of a solid particle.